Articles

Osteoarthritis is the most common form of long-term musculoskeletal disease, and is increasing in prevalence as societies become older. One of the key factors of living well with a disease that spans decades of a patient’s life is to diagnose the condition earlier, long before the disease limits function significantly, or causes disability.

Metabolic syndrome (MetS), also known as an insulin resistance syndrome, has been related to higher blood pressure outside of the normal range, insulin resistance, and increased fasting glucose levels.

This infographic explores the epidemiology, burden, and unmet need in IgA nephropathy (IgAN). Delving into the pathophysiology of IgAN, the infographic breaks down the different aspects of the kidney that are impacted by the inflammatory mediators endothelin-1 and angiotensin II.

The over-production of TNF-α can lead to chronic inflammation and organ damage in immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), axial spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Anti-TNF therapy is generally considered to be an effective, well-tolerated treatment option for the management of chronic inflammation in these conditions.

TDHS is characterised by variable hand symptoms ranging from a localised cellulitis, ulcer, or abscess, to a rapidly progressive gangrene and attendant overwhelming sepsis, which may result in permanent disability and fatality. Poor glycaemic control, poor nutrition, peripheral neuropathy, and low socioeconomic status are major risk factors contributing to the development of TDHS, usually in the setting of a preceding minor hand trauma.

A 54-year-old male tested positive in late February on a screening COVID-19 test performed after a family member’s test had become positive. A few weeks later, they presented to the emergency room at a different hospital centre with shortness of breath and fever.

As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting.

In 2017, colorectal cancer (CRC) accounted for 13% of new malignancy diagnoses in Canada. It is the second leading cause of cancer-related deaths in Canadian males, and the third leading cause of cancer related deaths in Canadian females.